Combinatorial Therapy: Targeting CD133+ Glioma Stem-like Cells with a Polysaccharide-Prodrug Complex Functionalised...

Area of Science:

• Oncology
• Immunotherapy
• Drug Delivery

Background:

• Cancer therapy is evolving to utilize the immune system for sustained tumor destruction.
• Combining chemotherapy with immunogens offers a dual approach to eliminate cancer cells and induce lasting immunity.
• Novel prodrugs integrating chemotherapeutic and immunomodulatory components are needed to enhance anticancer efficacy.

Purpose of the Study:

• To develop a novel prodrug by conjugating the anticancer drug 5-fluorouracil (5FU) with an extremophilic bacterial polysaccharide, Mauran (MR).
• To create a targeted drug delivery system using gold nanocages for specific delivery to CD133+ glioma cells.
• To evaluate the anticancer activity and drug release characteristics of the novel prodrug.

Main Methods:

• Modification of Mauran (MR) with 5-fluorouracil (5FU) to create the chloracetyl-MR-5FU prodrug.
• Encapsulation of the prodrug within gold nanocages for targeted delivery.
• In vitro assessment of anticancer activity against glioma cells.
• Ex vivo studies to demonstrate prodrug release.

Main Results:

• High encapsulation efficiency of 5FU during the MR modification process.
• Demonstrated in vitro anticancer activity of the chloracetyl-MR-5FU prodrug.
• Successful ex vivo demonstration of prodrug release.

Conclusions:

• The novel chloracetyl-MR-5FU prodrug, delivered via gold nanocages, exhibits potent anticancer effects against glioma cells.
• This approach effectively combines chemotherapy with polysaccharide-based immune modulation for enhanced cancer treatment.
• The prodrug demonstrates efficient drug loading and controlled release, paving the way for advanced glioblastoma therapies.